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ABSTRACT 
Tiffany Marie Peters: Explanatory Variables of Tobacco and Alcohol Cessation in Patients 
Undergoing Oral Biopsy 
(Under the direction of Valerie A. Murrah) 
 
Tobacco and alcohol are the predominant etiologic factors for oral cancer.  Studies show 
an association between disease severity and tobacco cessation.  Relationship between oral biopsy 
diagnosis and risk factor cessation is unknown. 
Patients diagnosed with hyperkeratosis, dysplasia or carcinoma were sent questionnaires 
addressing demographics and risk factor use.  Statistical analyses assessed whether behavior 
change was associated with the biopsy procedure and whether that change was related to 
diagnostic or demographic categories. 
Response rate was 37.4% (605/1619).  Higher percentages of subjects with more severe 
diagnoses quit cigarettes and alcohol following biopsy. Younger respondents were less likely to 
quit smoking prior to biopsy and more likely to be still smoking (p<0.01).  
For patients with suspicious oral lesions, clinicians should be aware that oral biopsy 
diagnosis is an important tool against risk factor addiction.  Younger patients are more likely to 
continue to be cigarette users even after controlling for severity of diagnosis. 
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CHAPTER 1: TOBACCO, ALCOHOL AND THE DENTAL PATIENT 
 
Introduction 
 
Approximately fifty percent of current smokers will die from a tobacco related disease.
1
  
Nearly one third of these current smokers will visit a dentist each year.
1, 2
  This places oral 
healthcare providers in a unique position to advance public health in the crusade against tobacco 
use.  This is especially relevant as tobacco, along with alcohol, are recognized as the 
predominant etiologic factors for squamous cell carcinoma of the oral cavity.
3-9
  It is recognized 
that oral cancer has an especially poor prognosis; regardless of scientific progress in treatment, 
there have been only minor improvements in survival rates of human papillomavirus (HPV)-
negative oral carcinomas over the past several decades.
4, 8, 10-14
  In addition, the risk of 
developing a second primary tumor is increased in tobacco and alcohol consumers according to 
the theory of “field cancerization.”15  Thus, strategies to decrease etiologic factors are critically 
needed.   
There are many elements that may play a role in risk factor cessation.  For instance, 
gender is implicated as a factor; one literature review found that men are more likely to stop 
smoking compared to women.
16
  In addition, it is noted that the severity of smoking-related 
disease, including head and neck cancer, has a positive association with cessation.
16, 17
  The 
experience of receiving a diagnosis for a serious illness is recognized as a “teachable moment” 
during which the patient is compelled to adhere to clinician advice.
18, 19
 
This knowledge can lead to more effectively targeted cessation strategies for health care 
providers seeking to aid in the cessation process.  Historically, strategies that have been used for
2 
 
cessation include behavioral therapy, such as counseling, and pharmacotherapy, including 
nicotine replacement products as well as bupropion hydrochloride (Wellbutrin®, Zyban®) and 
varenicline (Chantix®). However, according to the American Cancer Society, cessation attempts 
with pharmacotherapy yield only about a 25% quit rate.
20
  
In this study, we hypothesized that a malignant or premalignant oral biopsy diagnosis, in 
addition to providing objective data on which to base patient management, may also serve as a 
behavioral change agent to aid in risk factor cessation.  While cigarette use following malignant 
diagnosis has been assessed in previous studies, to our knowledge, the impact of a premalignant 
diagnosis on behavioral change has not been evaluated.  Also, our study addressed whether 
gender differences are present following specific oral biopsy results.  Knowledge of any 
relationship between oral biopsy diagnosis and risk factor cessation would be relevant for 
clinicians who deliver diagnoses and arrange for disease treatment.  These providers are in a 
unique position to influence at risk patients and reduce the overall use of the chief etiologic 
agents responsible for oral cancer.   
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Review of the Literature 
Tobacco and alcohol are recognized as the predominant etiologic factors for squamous 
cell carcinoma of the oral cavity, responsible for nearly three-quarters of all cases.
3-9
  Regardless 
of scientific progress in treatment, there have been only minor improvements in survival rates of 
human papillomavirus (HPV)-negative carcinomas over the past several decades; the two-year 
survival rate for patients treated with radiotherapy is still only about 50% when diagnosed at the 
regional stage.
4, 8, 10-14
  Moreover, the risk for developing a second primary tumor is increased in 
tobacco and alcohol consumers according to the theory of “field cancerization.”15  According to 
this theory, carcinogenic exposure occurs across a “field” of epithelium, leading to multiple 
discrete sites of dysplasia that progress toward cancer at differing rates depending on several 
factors, such carcinogen concentration.  Thus, a patient with a history of oral cancer likely 
harbors multiple other sites of precancerous changes throughout his oral cavity, even in areas 
where mucosa still appears clinically normal.
15
 
Overall, about 45-75% of all cancer patients are smokers at diagnosis,
19, 21
 and a study 
specific for head and neck cancer found that over 50% of patients used tobacco in the year 
preceding diagnosis.
17
  For patients who already have a malignant diagnosis, continued smoking 
is associated with a worse prognosis.  For example, persistent cigarette smoking has been linked 
with greater risk for initial tumor recurrence and lower overall survival.
22
  In addition, there is a 
higher risk for the development of a second primary tumor;
10
 continued use of tobacco as well as 
alcohol have been shown to significantly increase this risk.
23
  In terms of cancer therapy, 
smokers have reduced rates of radiation treatment response and survival as compared to those 
who quit prior to treatment.
24
  In addition, there are other negative side effects associated with 
radiation treatment and concurrent cigarette smoking, such as longer periods of mucositis.
25, 26
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Correspondingly, quitting smoking prior to accelerated radiation therapy results in decreased side 
effects.
25
  Furthermore, a decrease or discontinuation in cigarette use is associated with an 
overall decrease in mortality in head and neck cancer patients; the same is true for reducing or 
discontinuing alcohol consumption.
27
   
Study findings are inconsistent regarding the percentage of cancer patients who continue 
to use tobacco products following diagnosis.  For example, a literature review of smoking 
behavior in all cancer patients noted that 14-58% of those smoking at diagnosis failed to stop 
using cigarettes following treatment for cancer.
19
  Two studies specific for head and neck cancer 
found that about 65% of smokers stopped following diagnosis and treatment.
17, 18
  However, 
other studies indicate that only about 30% of current smokers with head and neck cancer quit 
after diagnosis and treatment.
25, 27
  Additional sources report that about 15% of those who 
survive cancer indicate current use of cigarettes.
21, 28
  Reported cessation rates may vary among 
studies due to differences in study design, such as length of follow-up, self-reported versus 
biochemically validated tobacco abstinence, cancer location, stage of cancer and type of 
treatment.  In addition, the Centers for Disease Control and Prevention (CDC) also found 
variation between different regions of the United States, with the greatest prevalence of cigarette 
use in cancer survivors in the South.
28
 
 There are many factors that may influence a patient to stop smoking.  One variable that 
has been elucidated through research is the severity of clinical disease; indeed, a review of the 
literature found that patients with more serious tobacco-related illnesses were more likely to 
comply with the recommendation for tobacco cessation.
16
  An association between severity of 
illness and tobacco cessation has been elucidated in both cardiovascular disease and head and 
neck cancer patients.  For example, smokers with lower serum creatine phosphokinase (CPK) 
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levels and briefer stays in an intensive care unit following myocardial infarction (MI) were more 
likely to resume smoking as compared to patients who suffered a more serious MI.
29
  Likewise, a 
smoking intervention study involving patients with coronary artery disease (CAD) found that 
those with more serious disease were more likely to be nonsmokers following intervention.
30
   In 
addition, a study investigating the impact of various psychosocial, demographic and smoking 
history variables on cigarette cessation in chronic obstructive pulmonary disease (COPD) 
patients found that COPD itself was the variable that most strongly affected cessation rates.
31
  
Similarly, a study found that patients with cases of head and neck cancer associated with a 
poorer prognosis were more likely to quit smoking as compared to those with a less severe 
prognosis; patients with a more advanced stage (II-IV) of cancer were significantly more likely 
to quit.  Interestingly, cancer site was also significantly associated with cessation as those with 
pharyngeal or laryngeal cancers were more likely to have quit (80%) compared to those with oral 
cancer (20%); however, it was also noted that those with oral cancer were less likely to have 
advanced disease.
17
    
 In addition to differences in tobacco cessation related to clinical disease severity, 
available literature also indicates a difference in tobacco cessation rates between males and 
females. One literature review noted gender as the most commonly reported variable associated 
with cessation; multiple studies found that men are more likely to stop smoking compared to 
women.
16
  An analysis of the National Health Interview Surveys data found that smoking 
cessation prevalence was lower in Caucasian women as compared to Caucasian men in adults 65 
years or older.
32
  Similarly, a smoking intervention study in patients with CAD found that males 
in the intervention group were more likely to be non-smokers at the six month follow-up time.
30
 
Finally, while the incidence of oral cancer is higher in males, the difference in rates between 
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males and females is becoming smaller over time; this is partially attributed to both a rise in use 
as well as longer duration of use in females.
10
 
Current research findings regarding elements associated with risk factor cessation can 
lead to more effectively targeted cessation strategies for health care providers seeking to aid in 
the cessation process.  Historically, strategies that have been used for cessation include 
behavioral therapy, such as counseling, and pharmacotherapy, including nicotine replacement 
products as well as bupropion hydrochloride (Wellbutrin®, Zyban®) and varenicline 
(Chantix®). However, according to the American Cancer Society, cessation attempts with 
pharmacotherapy yield only about a 25% quit rate.
20
  Furthermore, while it is clear that risk 
factor cessation is critical for both preventing oral cancer, as well as lowering the morbidity and 
mortality associated with treatment, the healthcare provider’s role in how to best aid cessation 
efforts is much less clear.  For instance, considerable emphasis is placed on promoting health 
knowledge and enhancing clinical outcome measures; however, studies have verified that 
improved knowledge in and of itself does not necessarily translate to a change in behavior or 
health.
33-35
  It has been postulated that patients are not likely to adopt new behaviors unless there 
is a perceptible benefit associated with this behavior; thus, reduced pain, better function or 
increased quality of life may serve as motivational factors, whereas a clinical measurement of 
disease may not be meaningful from a patient perspective.
36
  For this reason, it is critical to 
address risk factor cessation from a patient’s viewpoint of how the associated benefits may 
particularly impact his or her daily life.   
For some patients, one element that can render the discussion of risk factor cessation 
more personalized, and thus subsequent behavior change more likely, is the timing of the 
discussion.  For instance, it has been noted that patients who continue to smoke have a lower 
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perception of the risks associated with cigarettes and a reduced motivation to quit.
37-39
  However, 
the time period surrounding receipt of a malignant diagnosis and subsequent treatment may serve 
as a “teachable moment” during which the patient is compelled to adhere to clinician advice.18, 19  
Several studies note that health crises intensify awareness and may enhance the prospect of 
cessation.
16, 30, 40
  For example, one study found greater motivation to quit smoking as well as 
higher six-month abstinence rates in lung cancer patients as compared to controls, and thus 
suggested that clinicians “capitalize” on the time near initial diagnosis by providing valuable 
cessation support.
41
   
While it is important to convey the seriousness of an oral lesion and the etiologic role of 
tobacco or alcohol, it is equally important to remember that discussion of biopsy results should 
not be approached as a “scare tactic.”  It is thought that some patients with persistent tobacco use 
after a diagnosis of cancer may paradoxically reach for a pack of cigarettes because of the 
psychosocial stress that accompanies such a situation.  Fear, hopelessness or resignation may 
diminish the prospects of cessation.  Some studies have noted that cancer patients, while 
expressing interest in quitting, also convey low confidence in being able to do so and are only 
about half as likely to have attempted to quit in the past year as compared to all smokers.
21
 
While these findings are somewhat negative, healthcare providers should be inspired to 
approach cessation in a constructive manner as studies have also shown that patients with cancer 
have both the desire and the ability to overcome addictions.
19
  Patients who quit smoking after a 
cancer diagnosis attested to the value of support from family and friends.  For those surrounded 
by other tobacco users, having close contacts also engaged in quitting helped to reduce the 
appeal of cigarettes.
21
  Indeed, several studies report that tobacco abstinence in families helps 
maintain abstinence in the patient who is attempting to quit.
19, 42, 43
  In addition, for those cancer 
8 
 
survivors who have not stopped smoking, the majority express interest in both behavioral and 
pharmacotherapy cessation aids.  A wide variation was reported in the preferred type of desired 
behavioral intervention or pharmacotherapy; thus, it is recommended that cessation aids be 
personalized on a case by case basis.
21
 
Smoking cessation aids include both pharmacotherapy and behavioral approaches such as 
counseling.  Table 1 outlines the first line pharmacotherapy agents that have been approved by 
the United States Food and Drug Administration (FDA).  The U.S. Public Health Service has 
outlined evidence-based recommendations for cessation therapy.  The sequence of treatment 
starts with evaluating all patients for tobacco use, followed by recommending cessation for all 
current users.  The advice to quit should be unambiguous, urgent and individualized.  In terms of 
treatment, meta-analyses reveal that cessation therapy is most effective when counseling and 
pharmacotherapy are used in combination.  Nonetheless, combined therapy may not be 
appropriate for all patients, and it is important to note that counseling and pharmacotherapy are 
also beneficial when used individually.  Situations that may necessitate a single therapy include 
those in which a patient is unwilling to use both forms of therapy or in patient populations for 
which medications may be contraindicated or have not been proven to be effective.  These 
include adolescents, pregnant smokers, users of smokeless tobacco and light smokers.  Finally, it 
is important to be cognizant of the chronic nature of tobacco dependence; patients should receive 
follow up assessment and additional intervention as needed.
1
 
While there is clearly a need for involvement of healthcare providers in the fight against 
tobacco addiction, evidence suggests that actual engagement by clinicians is lacking.  For 
instance, a CDC study of current smokers found that approximately 50% of those who visited a 
physician within a twelve month period received cessation advice, and only about 10% who 
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visited a dental professional received cessation advice.
44
  Potential barriers to risk factor 
cessation discussion in a dental or oral surgery office may include the perception that the 
discussion must be extensive, or that such a discussion is not in the purview of oral healthcare 
providers.  However, for busy clinicians, it is noted that interventions of merely three minutes 
can significantly affect tobacco abstinence.
19, 45
  Also, presenting information prior to surgery 
regarding the adverse effect of smoking on surgical outcomes may provide further incentive for 
tobacco cessation.
19
  Further evidence for the role of oral healthcare providers in the fight against 
tobacco related diseases comes from studies that highlight the importance of early intervention 
for tobacco cessation in patients at risk for cancer.  For instance, a study focusing on patients 
with lung carcinoma found that those treated for nicotine dependence within three months of 
initial diagnosis had a greater likelihood of being tobacco free at the 6 month follow-up 
appointment as compared to those who received nicotine dependence treatment greater than three 
months after diagnosis.
19, 41
  For some oral cancer patients, dental providers are best situated to 
provide early intervention as they are the initial clinicians in a long journey of treatment that later 
proceeds to otolaryngology and oncology. Finally, the role of oral healthcare personnel as related 
to tobacco cessation is highlighted in studies that found higher tobacco abstinence rates 
associated with cessation interventions performed in conjunction with diagnostic work-ups or 
cancer screenings.
19, 46, 47
  This data suggests that risk factor cessation intervention may be 
particularly helpful at diagnosis and treatment planning appointments and recall examinations 
during which patients already undergo oral cancer screening exams. 
  In summary, squamous cell carcinoma of the oral cavity is a largely preventable disease, 
predominantly due to tobacco and alcohol abuse.  Existing literature points to a positive 
association between severity of clinical disease and rates of tobacco cessation and also indicates 
10 
 
differences in cessation rates according to gender.  In addition, while many patients diagnosed 
with cancer continue to smoke or consume alcohol, it is also known that a number of these 
patients will overcome addictions, whereas many others have an interest and desire to do so.  For 
this latter group, there are many things that clinicians can do to help patients in this arduous 
journey, and several of these factors are relevant to oral healthcare providers.  Firstly, the risk 
factor cessation discussion should be personalized for each patient and discussed in such a way 
as to elucidate the tangible benefits of quitting. Furthermore, while patients should be accurately 
informed of current health findings and the realistic dangers of continued risk factor use, this 
discussion should not be approached as a “scare tactic.”  Instead, encouragement for cessation 
should be emphasized.  Cessation aids should be personalized for each patient, and may include 
various approaches to counseling as well as pharmacotherapy.  Despite perceived barriers, oral 
healthcare providers have the opportunity and the means to serve as valuable team members in 
the struggle for tobacco cessation. 
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Table 1. Summary of pharmacotherapy options for smoking cessation, as adapted from “A 
Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update.”  Package 
inserts should be consulted for further safety and dosing information. OTC, over the counter; cig, 
cigarette. 
 
 
Drug Contraindications 
& Precautions 
Possible Side 
Effects 
Dosage Length of 
Treatment 
Accessibility 
Nicotine 
Replacement 
Therapy 
     
Nicotine gum  Oral irritation, 
nausea 
≤ 24 cig/ day: 
2 mg gum  
≥ 25 cig/ day: 
4 mg gum 
(up to 24 
pieces/day) 
≤ 12 wks OTC 
Nicotine 
lozenge 
 Nausea, acid 
reflux 
Time to 1
st
 
cig >30 min: 
2mg lozenge 
Time to 1
st
 
cig ≤ 30 min: 
4mg lozenge 
Use 4-20 
lozenges/ day 
≤ 12 wks OTC 
Nicotine 
patch 
 Local 
irritation, 
insomnia 
Available in 
21 mg, 14 mg 
and 7 mg 
patches to be 
tapered over 
time 
Varies  OTC, 
prescription 
Nicotine nasal 
spray 
 Nasal irritation 8-40 
doses/day 
3-6 months prescription 
Nicotine 
inhaler 
 Local 
oropharyngeal 
irritation 
6-16 
cartridges/day 
≤ 6 months prescription 
Other      
Bupropion History of seizures 
or eating disorder 
Xerostomia, 
insomnia, 
seizures 
Start 1-2 wks 
prior to quit 
date: 
150 mg q 
morning for 3 
days, then 
150 mg bid 
7-12 wks, 
maintenance 
up to 6 
months 
prescription 
12 
 
Varenicline Kidney disease Nausea, 
insomnia, 
depression & 
other 
psychiatric 
symptoms 
Start 1 wk 
prior to quit 
date: 0.5 mg/ 
day for 3 
days, 0.5 mg 
bid for 4 
days, then 1 
mg bid 
3-6 months prescription 
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CHAPTER 2: CANCER RISK FACTOR CESSATION AND ORAL BIOPSY 
Introduction 
Tobacco and alcohol are recognized as the predominant etiologic factors for squamous 
cell carcinoma of the oral cavity, responsible for nearly three-quarters of all cases.
3-9
  Regardless 
of scientific progress in treatment, there have been only minor improvements in survival rates of 
human papillomavirus (HPV)-negative carcinomas over the past several decades; the two-year 
survival rate for patients treated with radiotherapy is still only about 50% when diagnosed at the 
regional stage.
4, 8, 10-14
  Moreover, the risk for developing a second primary tumor is increased in 
tobacco and alcohol consumers according to the theory of “field cancerization.”15  Thus, 
strategies to decrease etiologic factors are critically needed.  It was hypothesized that oral biopsy 
diagnosis, in addition to providing objective data on which to base patient management, may 
serve as a behavioral change agent to aid in risk factor cessation.   
Overall, about 45-75% of all cancer patients are smokers at diagnosis,
19, 21
 and a study specific 
for head and neck cancer found that over 50% of patients used tobacco in the year preceding 
diagnosis.
17
  For patients who already have a malignant diagnosis, continued smoking is 
associated with a worse prognosis.  For example, persistent cigarette smoking has been linked 
with greater risk for initial tumor recurrence and lower overall survival.
22
  In addition, there is a 
higher risk for the development of a second primary tumor;
10
 continued use of tobacco as well as 
alcohol have been shown to significantly increase this risk.
23
  In terms of therapy, smokers have 
reduced rates of radiation treatment response and survival, as compared to those who quit prior 
to treatment.
24
  In addition, there are other negative side effects associated with radiation 
14 
 
treatment and concurrent cigarette smoking, such as longer periods of mucositis.
25, 26
  
Correspondingly, quitting smoking prior to accelerated radiation therapy results in decreased side 
effects.
25
  Furthermore, a decrease or discontinuation in cigarette use is associated with an 
overall decrease in mortality in head and neck cancer patients; the same is true for reducing or 
discontinuing alcohol consumption.
27
   
Study findings are inconsistent regarding the percentage of cancer patients who continue 
to use tobacco products following diagnosis.  For example, a literature review of smoking 
behavior in all cancer patients noted that 14-58% of those smoking at diagnosis failed to stop 
using cigarettes following treatment for cancer.
19
 Two studies specific for head and neck cancer 
found that about 65% of smokers stopped following diagnosis and treatment.
17, 18
  However, 
other studies indicate that only about 30% of current smokers with head and neck cancer quit 
after diagnosis and treatment.
25, 27
  Reported cessation rates may vary among studies due to 
differences in study design, such as length of follow-up, self-reported versus biochemically 
validated tobacco abstinence, cancer location, stage of cancer and type of treatment. 
 There are many factors that may influence a patient to stop smoking.  One variable that 
has been elucidated through research is the severity of clinical disease; indeed, a review of the 
literature found that patients with more serious tobacco-related illnesses were more likely to 
comply with the recommendation for tobacco cessation.
16
  An association between severity of 
illness and tobacco cessation has been elucidated in both cardiovascular disease and head and 
neck cancer patients.  For example, smokers with lower serum creatine phosphokinase (CPK) 
levels and briefer stays in an intensive care unit following myocardial infarction (MI) were more 
likely to resume smoking as compared to patients who suffered a more serious MI.
29
  Likewise, a 
smoking intervention study involving patients with coronary artery disease (CAD) found that 
15 
 
those with more serious disease were more likely to be nonsmokers following intervention.
30
   In 
addition, a study investigating the impact of various psychosocial, demographic and smoking 
history variables on cigarette cessation in chronic obstructive pulmonary disease (COPD) 
patients found that COPD itself was the variable that most strongly affected cessation rates.
31
  
Similarly, a study found that patients with cases of head and neck cancer associated with a 
poorer prognosis were more likely to quit smoking as compared to those with a less severe 
prognosis; patients with a more advanced stage (II-IV) of cancer were significantly more likely 
to quit.  Interestingly, cancer site was also significantly associated with cessation as those with 
pharyngeal or laryngeal cancers were more likely to have quit (80%) compared to those with oral 
cancer (20%); however, it was also noted that those with oral cancer were less likely to have 
advanced disease.
17
   
 Given the high morbidity and mortality of head and neck cancer, clinicians should 
maximize opportune occasions in which to address risk factor cessation with patients.  The time 
period surrounding receipt of a malignant diagnosis and subsequent treatment may serve as a 
“teachable moment” during which the patient is compelled to adhere to clinician advice.18, 19 
Several studies note that health crises intensify awareness and may enhance the prospect of 
cessation.
16, 30, 40
  For example, one study found greater motivation to quit smoking as well as 
higher six-month abstinence rates in lung cancer patients as compared to controls, and thus 
suggested that clinicians “capitalize” on the time near initial diagnosis by providing valuable 
cessation support.
41
   
 In addition to differences in tobacco cessation related to clinical disease severity, 
available literature also indicates a potential difference in tobacco cessation rates between males 
and females. One literature review noted gender as the most commonly reported variable 
16 
 
associated with cessation; multiple studies found that men are more likely to stop smoking 
compared to women.
16
  An analysis of the National Health Interview Surveys data found that 
smoking cessation prevalence was lower in Caucasian women as compared to Caucasian men in 
adults 65 years or older.
32
  Similarly, a smoking intervention study in patients with CAD found 
that males in the intervention group were more likely to be non-smokers at the six month follow-
up time.
30
 Finally, while the incidence of oral cancer is higher in males, the difference in rates 
between males and females is becoming smaller over time; this is partially attributed to both a 
rise in use as well as longer duration of use in females. 
10
 
In summary, existing literature points to an association between severity of clinical 
disease and rates of tobacco cessation and also indicates differences in cessation rates according 
to gender.  This knowledge can lead to more effectively targeted cessation strategies for health 
care providers seeking to aid in the cessation process.  Historically, strategies that have been 
used for cessation include behavioral therapy, such as counseling, and pharmacotherapy, 
including nicotine replacement therapy as well as bupropion hydrochloride (Wellbutrin®, 
Zyban®) and varenicline (Chantix®). However, according to the American Cancer Society, 
cessation attempts with pharmacotherapy yield only about a 25% quit rate.
20
  In this study, we 
hypothesized that a malignant or premalignant oral biopsy diagnosis may also serve as a 
behavioral change agent to aid in risk factor cessation.  To our knowledge, the impact of a 
premalignant diagnosis on behavioral change has not been evaluated.  Also, our study addressed 
whether the gender differences observed previously in association with risk factor cessation 
would also be present following specific oral biopsy results.  Knowledge of the relationship 
between oral biopsy diagnosis and risk factor cessation can be highly significant for clinicians 
who deliver diagnoses and arrange for disease treatment.  These providers are in a unique 
17 
 
position to influence at risk patients and reduce the overall use of the chief etiologic agents 
responsible for oral cancer. 
18 
 
Materials and Methods  
This was an observational study that utilized a survey design.  A consecutive sample of 
potential subjects was identified through the University of North Carolina (UNC) oral pathology 
laboratory database after obtaining UNC Institutional Review Board and School of Dentistry 
approval (see Appendix 1 for additional information).  Potential subjects included any patients 
within a designated two-year period (August 1, 2007-July 31, 2009) who had an oral tissue 
specimen sent to the UNC oral pathology laboratory and received a diagnosis of hyperkeratosis, 
dysplasia (mild, moderate or severe) or carcinoma (in situ, verrucous or squamous cell).  
Subjects with a diagnosis of hyperkeratosis were considered as a control group.  Subjects with lip 
carcinoma of the vermillion border or those with actinic damage, as well as subjects under 
eighteen years of age, were excluded.   
A questionnaire created using Teleform was sent in the mail to potential subjects (see 
Appendix 2).  A second questionnaire was sent to non-responders.  Returned questionnaires were 
scanned and verified, and data was stored in an ACCESS database.  Subjects were asked to 
record demographic information as well as information about previous or current tobacco use 
and alcohol use.  Cigarettes and smokeless tobacco were considered separately with a combined 
section for pipes and cigars.  For each product, subjects were asked, “Have you ever used this 
product?”  For those who responded “yes,” additional questions followed pertaining to product 
usage.  Subjects were asked if they had changed their usage.  Possible answers included no 
change in usage, reduced usage, quit after biopsy and quit prior to biopsy. 
Demographic characteristics and percentages of subjects in product use categories were 
summarized using descriptive statistics.  For race, respondents were categorized as Caucasian or 
non-Caucasian due to the small number of non-Caucasian respondents.  For age, a highly skewed 
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distribution led to categorization based on quartiles of the entire sample.  Age quartiles were 
defined as age 21-52 years, 53-61 years, 62-68 years and 69-98 years.  Statistical analysis was 
focused on results associated with use of cigarettes and alcohol as relatively few subjects 
reported use of smokeless tobacco or pipes or cigars.  The data from five subjects was eliminated 
from analysis due to inconsistency between responses (i.e. reporting never use of a product, then 
subsequently reporting amount of use).  Behavior change categories were collapsed and defined 
as “quit prior to biopsy,” “quit after biopsy” and “still using” for those subjects with no change in 
usage and those with reduced usage.  Behavior change responses were considered ordinal data 
with “still using” as worst, “quit after biopsy” as satisfactory and “quit before biopsy” as the best 
outcome. 
Bivariate analysis was performed using a chi-square test of independence, or Fisher’s 
exact test when appropriate, to compare diagnostic categories for differences in gender, race and 
age, and also to compare those who never used cigarettes or alcohol versus those who did to 
identify differences in diagnostic category, gender, race or age among these groups.  Bivariate 
analysis with a Cochran-Mantel-Haenzel row mean score test with modified ridits for ordinal 
data was used to determine if behavior change was related to diagnostic category, gender, race or 
age.  In addition, multivariate analysis using the proportional odds model was also used to assess 
if behavior change was related to diagnostic category, gender, race or age.  The level of 
significance was set at 0.05. 
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Results  
 605 out of 1619 potential subjects returned a questionnaire for a response rate of 37.4%.  
Demographic characteristics of respondents are summarized in Table 2.  Some categories 
combine to less than the total number of respondents as not all respondents answered all 
questions.  Caucasians comprised 85% of those who responded, and females comprised 49.5%.  
There was no statistically significant difference among diagnostic categories with respect to the 
proportion of Caucasians or the proportion of females who responded.   
The carcinoma group had the highest response rate with 42.6% of potential subjects 
returning a survey.  Overall, subjects with dysplasia comprised 53.7% of the total respondents.  
Table 3 summarizes reported changes in carcinogenic product usage.  The product with the 
highest reported frequency of ever use was alcohol, followed in decreasing frequency by 
cigarettes, pipes and cigars, and smokeless tobacco (Figure 1). 
Bivariate analysis indicated a statistically significant difference among diagnostic 
categories with respect to distribution of age (p= 0.04); respondents with a diagnosis of 
carcinoma were older than those in the other diagnostic categories.  There were also differences 
with respect to ever use of carcinogenic products.  Across diagnostic categories, there was a 
significant difference in the proportion of those who reported never using cigarettes, with fewer 
carcinoma subjects indicating this response (p<0.01).  There was no significant difference among 
diagnostic categories in the proportion of those who never used alcohol.  Comparison by race 
indicated no significant difference in the proportion of Caucasians versus non-Caucasians who 
never used cigarettes, but a higher proportion of Caucasians reported using alcohol (p<0.01).  
For age, there was no significant difference in the proportion of those who never used cigarettes 
among the age groups, but older respondents were significantly more likely to report never using 
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alcohol (p<0.01).  Comparison of males and females indicated no significant difference in the 
proportion of males versus females who never used cigarettes, but females were more likely to 
report never using alcohol (p<0.01).  
With respect to the effect of explanatory variables on change in cigarette use (Table 3), 
bivariate analysis indicated no significant difference among diagnostic categories.  Race and 
gender were also not significantly associated with change in cigarette usage.  There was a 
significant difference among age groups in behavior change, with respondents in the first and 
second quartiles being less likely to quit using cigarettes prior to biopsy (p<0.01).   
With respect to the effect of explanatory variables on change in alcohol use (Table 4), 
bivariate analysis indicated no significant difference among diagnostic categories.  Gender and 
age were also not significantly associated with change in alcohol use.  Race was significantly 
associated with change in alcohol use, with Caucasians being less likely to quit using alcohol 
prior to biopsy than non-Caucasians (p<0.01).   
Analysis using the proportional odds model for change in cigarette use showed similar 
findings as the bivariate analysis (Table 5).  The score test for the proportional odds assumption 
was not statistically significant (p=0.28), indicating the odds ratios were consistent for all logits.  
The global test for behavioral change in cigarette usage was statistically significant (p<0.01), 
with age (p<0.01) contributing significantly to the variability in the respondents’ change in 
cigarette use after controlling for all other explanatory variables.  Respondents in the first and 
second quartiles were less likely to quit prior to biopsy and more likely to be still using 
cigarettes.  Compared to those in the fourth quartile of age, respondents in the first quartile are 
approximately 3.7 times more likely to not quit using cigarettes prior to biopsy or to still be 
smoking (95% CI: 1.98-6.91).  Respondents in the 2
nd
 quartile of age are approximately 2.4 
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times less likely to quit before a biopsy and are more likely to still be smoking than those in the 
4
th
 quartile (95% CI: 1.4-4.4).  Race was a marginally statistically significant contributor to the 
respondent’s change in cigarette use after controlling for all other explanatory variables.  
Caucasians were more likely to quit smoking prior to biopsy than non-Caucasians (OR=0.54; 
95% CI= 0.3-0.99). 
Analysis using the proportional odds model for change in alcohol use indicated similar 
findings as the bivariate analysis (Table 6).  The score test for the proportional odds assumption 
was not statistically significant (p=0.74), indicating the odds ratios were consistent for all logits.  
The global test for behavioral change in alcohol usage was statistically significant (p<0.05), with 
race (p<0.01) contributing significantly to the variability in the respondents’ change in alcohol 
usage after controlling for the other explanatory variables. 
Tables 7 and 8 summarize the behavioral response for subjects who were users of 
carcinogenic products at the time of biopsy.  Higher percentages of subjects with clinically more 
severe diagnoses quit following biopsy.  This was true for both cigarettes and alcohol, with 
higher quitting percentages for cigarettes. 
 
 
 
 
 
 
 
 
  
Table 2. Demographic characteristics and diagnostic categories of respondents (N=605).  Percentages in “Total” column are 
representative of number of respondents within each demographic category.  Percentages in other columns are representative of 
number or respondents in each diagnostic category.   
 
                                           N        (%) 
Variable Total Carcinoma Dysplasia Hyperkeratosis P-value 
Gender      
  Male 300      (50.5%) 22      (7.3%) 158      (52.7%) 120      (40.0%)  
  Female 294      (49.5%) 17      (5.8%) 158      (53.7%) 119      (40.5%) 0.75 
Age      
Q
1
 (21-52 years) 134     (22.6%) 4      (10.3%) 67      (21.1%) 63      (26.7%)  
Q
2 
(53-61 years) 150     (25.3%) 7      (18.0%) 79      (24.9%) 64      (27.1%)  
Q
3 
(62-68 years) 145     (24.5%) 10     (25.6%) 85      (26.8%) 50      (21.2%)  
Q
4 
(69-98 years) 163     (27.5%) 18     (46.2%) 86      (27.1%) 59      (25.0%) 0.04 
Race      
Caucasian 503    (85.8%) 33      (6.6%) 275     (54.7%) 195    (38.8%) 0.32 
Non-Caucasian 83      (14.2%) 7        (8.4%) 38       (45.8%) 38      (45.8%)  
2
3
 
24 
 
Table 3. Changes in Carcinogenic Product Usage. N= 605.  
 
 Alcohol 
N       (%) 
Cigarettes 
N       (%) 
Pipes/ Cigars 
N        (%) 
Smokeless Tobacco 
N       (%) 
Never Used 125    (21.1%) 278    (46.2%) 479     (84.2%) 496     (85.5%) 
Quit Prior to 
Biopsy 
48      (8.1%) 130    (21.6%) 25      (4.4%) 11      (1.9%) 
Quit After 
Biopsy 
37      (6.2%) 69      (11.5%) 22      (3.9%) 32     (5.5%) 
Reduced Use 
Since Biopsy 
54      (9.1%) 47      (7.8%) 8        (1.4%) 20     (3.5%) 
No change since 
biopsy 
329    (55.5%) 78      (13.0%) 35        (6.2%) 21     (3.6%) 
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Figure1. Carcinogenic product usage prior to and after oral biopsy. 
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Table 4.  Bivariate analysis for cigarette usage, according to gender, race, age quartiles and 
diagnosis.  N=324 ever cigarette users.   
 
 
 Still using 
N      (%) 
Quit after biopsy 
N      (%) 
Quit prior to biopsy 
N      (%) 
P-value 
All 125     (38.6%) 69      (21.3%) 130    (40.1%)  
   Male 
   Female 
63       (36.8%) 
61       (40.9%) 
40      (23.9%) 
28      (18.8%) 
68      (39.8%) 
60      (40.3%) 
0.72 
   Caucasian 
   Non-Caucasian 
101     (37.4%) 
21       (42.9%) 
54      (20.0%) 
14      (28.6%) 
115    (42.6%) 
14      (28.6%) 
0.15 
   Q1 
   Q2 
   Q3 
   Q4 
39       (57.4%) 
37       (46.8%) 
23       (27.7%) 
23       (25.6%) 
12      (17.6%) 
16      (20.3%) 
17      (20.5%) 
23      (25.6%) 
17      (25.0%) 
26      (32.9%) 
43      (51.8%) 
44      (48.9%) 
<0.01 
   Hyperkeratosis 
   Dysplasia 
   Carcinoma 
48       (43.6%) 
70       (36.8%) 
7         (29.2%) 
16      (14.6%) 
47      (24.7%) 
6        (25.0%) 
46      (41.8%) 
73      (38.4%) 
11      (45.8%) 
0.66 
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Table 5.  Bivariate analysis for alcohol usage, according to gender, race, age quartiles and 
diagnosis.  N= 468 ever alcohol users.   
 
 Still using 
N       (%) 
Quit after biopsy 
N      (%) 
Quit prior to biopsy 
N      (%) 
P-value 
All 383 37 48  
   Male 
   Female 
217      (80.4%) 
161      (84.3%) 
23     (8.5%) 
12     (6.3%) 
30     (11.1%) 
18     (9.4%) 
0.30 
   Caucasian 
   Non-Caucasian 
345     (84.4%) 
31       (63.3%) 
26     (6.4%) 
9       (18.4%) 
38     (9.3%) 
9       (18.4%) 
<0.01 
   Q1 
   Q2 
   Q3 
   Q4 
96       (86.5%) 
111     (85.4%) 
85       (75.2%) 
87       (79.8%) 
8       (7.2%) 
8       (6.2%) 
12     (10.6%) 
8       (7.3%) 
7       (6.3%) 
11     (8.5%) 
16     (14.2%) 
14     (12.8%) 
0.09 
   Hyperkeratosis 
   Dysplasia 
   Carcinoma 
153     (83.2%) 
208     (82.9%) 
22       (66.7%) 
12     (6.5%) 
18     (7.2%) 
7       (21.2%) 
19    (10.3%) 
25    (10.0%) 
4      (12.1%) 
0.10 
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Table 6.  Multivariate analysis for cigarette usage, according to gender, race, age quartiles and 
diagnosis.  Probabilities modeled are those for the worst category.  N=324 ever cigarette users.  
a
OR: odds ratio. 
b
CI: confidence interval of odds ratio.   
 
 Still using 
N      (%) 
Quit after 
biopsy 
N      (%) 
Quit prior to 
biopsy 
N      (%) 
OR
a
 95% CI
b
 
P-value 
All 125     (38.6%) 69      (21.3%) 130    (40.1%)    
Male 
Female 
63       (36.8%) 
61       (40.9%) 
40      (23.9%) 
28      (18.8%) 
68      (39.8%) 
60      (40.3%) 
0.97 
1 
0.63-1.49 0.88 
Caucasian 
Non-Caucasian 
101     (37.4%) 
21       (42.9%) 
54      (20.0%) 
14      (28.6%) 
115    (42.6%) 
14      (28.6%) 
0.54 
1 
0.30-1.00 0.049 
Q1 
Q2 
Q3 
Q4 
39       (57.4%) 
37       (46.8%) 
23       (27.7%) 
23       (25.6%) 
12      (17.6%) 
16      (20.3%) 
17      (20.5%) 
23      (25.6%) 
17      (25.0%) 
26      (32.9%) 
43      (51.8%) 
44      (48.9%) 
3.70 
2.44 
1.11 
1 
1.98- 6.91 
1.36- 4.37 
0.62- 1.97 
<0.01 
Hyperkeratosis 
Dysplasia 
Carcinoma 
48       (43.6%) 
70       (36.8%) 
7         (29.2%) 
16      (14.6%) 
47      (24.7%) 
6        (25.0%) 
46      (41.8%) 
73      (38.4%) 
11      (45.8%) 
1.07 
1.16 
1 
0.48-2.58 
0.50-2.69 
0.91 
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Table 7.  Multivariate analysis for alcohol usage, according to gender, race, age quartiles and 
diagnosis.  Probabilities modeled are those for the worst category.  N= 468 ever alcohol users. 
a
OR: odds ratio.  
b
CI: confidence interval of odds ratio.   
 
 
 Still using 
N       (%) 
Quit after 
biopsy 
N      (%) 
Quit prior to 
biopsy 
N      (%) 
OR
a
 95% CI
b
 
P-value 
All 383 37 48    
Male 
Female 
217      (80.4%) 
161      (84.3%) 
23     (8.5%) 
12     (6.3%) 
30     (11.1%) 
18     (9.4%) 
0.73 
1 
0.44-1.22 0.23 
Caucasian 
Non-Caucasian 
345     (84.4%) 
31       (63.3%) 
26     (6.4%) 
9       (18.4%) 
38     (9.3%) 
9       (18.4%) 
3.17 
1 
1.63-6.15 <0.01 
Q1 
Q2 
Q3 
Q4 
96       (86.5%) 
111     (85.4%) 
85       (75.2%) 
87       (79.8%) 
8       (7.2%) 
8       (6.2%) 
12     (10.6%) 
8       (7.3%) 
7       (6.3%) 
11     (8.5%) 
16     (14.2%) 
14     (12.8%) 
1.71 
1.48 
0.69 
1 
0.79-3.69 
0.73-3.00 
0.36-1.32 
0.05 
Hyperkeratosis 
Dysplasia 
Carcinoma 
153     (83.2%) 
208     (82.9%) 
22       (66.7%) 
12     (6.5%) 
18     (7.2%) 
7       (21.2%) 
19    (10.3%) 
25    (10.0%) 
4      (12.1%) 
2.09 
1.82 
1 
0.86-5.04 
0.78-4.22 
0.26 
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Table 8. Behavioral change in subjects who were smokers at time of biopsy. 
Percentage of subjects per diagnostic category who quit smoking following biopsy. N= 194 
smokers at time of biopsy 
 
 
 Still Using After Bx. 
N     (%) 
Quit After Bx. 
N    (%) 
All 125    (64.4%) 69     (35.6%) 
  Hyperkeratosis 48      (75%) 16     (25%) 
  Dysplasia 70      (59.8%) 47     (40.2%) 
  Carcinoma 7        (53.8%) 6       (46.2%) 
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Table 9. Behavioral change in subjects who were alcohol consumers at time of biopsy. 
Percentage of subjects per diagnostic category who quit drinking alcoholic beverages following 
biopsy. N= 420 alcohol consumers at time of biopsy. 
 
 Still Drinking After Bx. 
N     (%) 
Quit After Bx. 
N    (%) 
All 383      (91.2%) 37      (8.8%) 
  Hyperkeratosis 153      (92.7%) 12      (7.3%) 
  Dysplasia 208      (92%) 18      (8.0%) 
  Carcinoma 22        (75.9%) 7        (24.1%) 
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Discussion 
To our knowledge, this is the first study to address the effect of a premalignant diagnosis 
on oral cancer risk factor cessation.  For those subjects using cigarettes or alcohol at the time of 
biopsy, higher percentages of subjects with clinically more severe diagnoses quit following 
biopsy, including higher percentages of subjects with dysplasia quitting as compared to those 
with hyperkeratosis (Tables 8 and 9).  This is an encouraging finding given that dysplasia has 
been shown to be a potentially reversible process. 
48, 49
 
When all subjects who reported ever using cigarettes were combined, age was the 
explanatory variable found to be significantly associated with cessation (Table 4).  The finding 
of younger subjects being both less likely to quit prior to biopsy as well as more likely to be still 
smoking appears to conflict with data from the most recent National Health Interview Surveys 
(NHIS), which found that adults ≥ 65 years had a lower interest in smoking cessation and made 
fewer attempts at quitting.
50
  It is postulated that differences may be attributable to sampling, as 
this study focused on patients with a history of a suspicious oral lesion as opposed to smokers in 
the general population.  It is possible that suspicious oral lesions may be less alarming to 
younger patients, who may consider cancer to be a phenomenon associated with older age.   
When combining all subjects who reported ever using alcohol, race was significantly 
associated with cessation after controlling for other variables, with Caucasians being less likely 
to quit consuming alcohol prior to biopsy (Table 5).  In addition, a higher proportion of 
Caucasians reported ever use of alcohol.   This is consistent with findings from other studies that 
noted Caucasians to have the highest rates of current alcohol consumption
51
 and high rates of 
binge drinking, although the highest prevalence of alcohol dependence was observed in 
American Indians or Alaskan Natives.
52
  However, findings in this study associated with race 
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should be interpreted cautiously as non-Caucasians comprised less than 15% of respondents.  
The small number of non-Caucasian respondents may be attributable to several possible factors, 
including a potentially smaller pool of non-Caucasian subjects undergoing oral biopsy, or 
possibly because non-Caucasians were less likely to return a questionnaire.  A previous 
epidemiological study noted that African Americans were more reluctant to take part in medical 
studies as compared to Caucasians, which was chiefly attributable to reduced trust in medical 
research.
53
 
Carcinoma subjects were significantly more likely to be older than subjects with 
hyperkeratosis or dysplasia (Table 2).  This may be related to the fact that older patients 
theoretically have longer periods of exposure to risk factors; however, it may also be due to the 
fact that the likelihood of developing cancer increases with age.
54
  Significantly fewer carcinoma 
subjects reported never using cigarettes as compared to those in other diagnostic categories, 
which is compatible with current models of tobacco use as a risk factor for oral cancer.   
Data from this and other studies highlights the fact that a large percentage of patients at 
risk for oral cancer continue to use carcinogenic products.  Smoking cessation advice from 
healthcare personnel results in more attempts at quitting and improved utilization of 
pharmacotherapy agents shown to improve the rates of smoking cessation by two to three times.
1, 
50
  However, while there is clearly a need for involvement of healthcare providers in the fight 
against tobacco addiction, evidence suggests that actual engagement by clinicians is lacking.  For 
instance, a CDC study of current smokers found that approximately 50% of those who visited a 
physician within a twelve month period received cessation advice, whereas only about 10%  who 
visited a dental professional received cessation advice.
44
   
It is imperative that oral care providers increase efforts to aid patients in risk factor 
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cessation.  Nevertheless, the role of the healthcare provider in cessation efforts is not always 
readily evident.  For instance, considerable emphasis is placed on promoting health knowledge 
and enhancing clinical outcome measures; however, studies have verified that improved 
knowledge in and of itself does not necessarily translate to a change in behavior or health.
33-35
  It 
has been postulated that patients are not likely to adopt new behaviors unless there is a 
perceptible benefit associated with this behavior; thus, reduced pain, better function or increased 
quality of life may serve as motivational factors, whereas a clinical measurement of disease may 
not be meaningful from a patient perspective.
36
  For this reason, it is critical to address risk factor 
cessation from a patient’s viewpoint of how the associated benefits may particularly impact his 
or her daily life.  For instance, it has been noted that patients who continue to smoke have a 
lower perception of the risks associated with cigarettes and a reduced motivation to quit.
37-39
  
According to this study, oral biopsy is an important initial step in risk factor cessation for those 
patients with oral lesions.  Informing a patient that surgical removal of a suspicious lesion is 
recommended enlightens the patient to the fact that his health may be in jeopardy and that a 
painful procedure is recommended in order to determine this.  Also, delivery of the biopsy 
diagnosis also serves as an opportunity to highlight unequivocally how the patient’s tissues are 
being affected by risk factor use as well as how cessation will be directly beneficial.  For those 
diagnosed with hyperkeratosis, patients should be informed that although these lesions are not 
considered precancerous, hyperkeratosis is a change that tissues undergo as a means of 
protection to an irritant.  Chronic exposure to products that cause tissue injury leads to increased 
cell division as a means of replacing damaged cells, and this subsequently leads to increased risk 
for neoplasia due to the additional opportunity for errors in genetic replication.
55
 This concept 
coincides with the finding that, when followed over time, some lesions initially diagnosed as 
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benign hyperkeratosis later progress to squamous cell carcinoma.
56, 57
  In this study, lower 
percentages of risk factor cessation were found in subjects with hyperkeratosis, perhaps 
indicating that these patients have a misguided sense of wellness.   
As previously mentioned, relatively few oral care providers currently address smoking 
cessation with patients.
44
  Clinicians may have several perceived barriers to discussing risk factor 
cessation with patients, including the potential time-consuming nature of such a conversation, 
especially if the discussion is to be personalized for each patient.  However, for busy clinicians, 
it is noted that interventions of merely three minutes can significantly affect tobacco 
abstinence.
19, 45
  Another possible concern is that a patient will be encumbered with too much 
information at once or unable to process additional information after an alarming diagnosis.  
However, the vast majority of patients who undergo an oral biopsy have several possible 
appointments in relation to the biopsy, including an exam at a referring provider’s office, a 
consult with a specialist, a surgery appointment and post-operative appointment(s) for follow-up 
and delivery of the diagnosis.  Each of these can serve as a “touch point” for communication.  
Discussion of risk factor cessation can be incremental with introduction prior to surgery and 
follow-up dialogue at subsequent appointments.  Also, presenting information prior to surgery 
regarding the adverse effect of smoking on surgical outcomes may provide further incentive for 
tobacco cessation.
19
  Thus, both referring providers and specialists have the opportunity to assist 
patients in the challenging endeavor of overcoming an addiction.   
Further evidence for the role of oral healthcare providers in the fight against tobacco 
related diseases comes from studies that highlight the importance of early intervention for 
tobacco cessation in patients at risk for cancer.  For instance, a study focusing on lung carcinoma 
patients found that those treated for nicotine dependence within three months of initial diagnosis 
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had a greater likelihood of being tobacco free at the 6 month follow-up appointment as compared 
to those who received nicotine dependence treatment greater than three months after diagnosis.
19, 
41
  As oral biopsies often occur in a dental office, these providers may see oral cancer patients 
prior to the patient being referred to otolaryngology or oncology, and the initial tobacco 
cessation intervention should not be postponed for these other doctors.  Finally, the role of oral 
healthcare personnel as related to tobacco cessation is highlighted in studies that found higher 
tobacco abstinence rates associated with cessation interventions performed in conjunction with 
diagnostic work-ups or cancer screenings.
19, 46, 47
  Thus, research suggests that risk factor 
cessation intervention may be particularly helpful when performed at diagnosis and treatment 
planning appointments, in addition to recall examination appointments, as the patient is already 
undergoing an oral cancer screening exam.  Furthermore, implementing a protocol for the 
discussion of risk factor cessation at these appointments ensures that this important aspect of 
patient care will not be overlooked, even for patients that do not yet have a clinically visible 
lesion. 
This study utilized self-reporting of risk factor use, which replicates a real-world clinic 
setting in terms of determining a patient’s history of tobacco and alcohol use.  Nevertheless, this 
introduces a potential limitation of the study as this method may be prone to recall bias or 
misreporting.  Some studies using biochemical analysis have documented inaccuracies in the 
self-reporting of tobacco use.
58-60
  The likelihood of inaccuracy appears to be increased in 
patients who claim to be recent quitters.
58, 61
  In addition, pregnant patients or patients with 
tobacco-related diseases may also be more likely to underreport tobacco use, perhaps because 
these patients feel more social obligation to quit smoking.
58-60
  Conversely, other studies 
document good correlation between self-reported cigarette use and biochemical analysis of 
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nicotine metabolite levels; this was found in both studies of selected populations, such as 
pregnant patients and head and neck cancer patients, as well as in a meta-analysis of studies 
involving the general population.
61-63
  In addition, it is noted that self-reported data obtained in a 
research setting is frequently more accurate than that obtained in a clinical setting, as the 
research setting is deemed to be more neutral.
60
 
 Due to the controversy associated with self-reporting of tobacco use, a future study of 
this nature that utilizes biochemical validation of nicotine exposure may prove useful.  In 
addition, this study was limited by a cross-sectional design; a longitudinal study would be useful 
as risk factor usage may vary over time following diagnosis and treatment.  For patients that quit 
prior to biopsy, it would be beneficial to know if the patient quit several years prior to the biopsy 
procedure, or if cessation occurred closer to the time of surgery as the latter cases could be 
potentially attributable to the seriousness of the need for biopsy.  Furthermore, carcinogenic 
product usage at the time of biopsy should be used as an inclusion criterion in order to focus on 
oral biopsy diagnosis as associated with risk factor cessation.  Finally, future studies may want to 
address intervention measures designed to improve patients’ sense of coherence in order to 
enrich quality of life as associated with oral health, specifically the prevention of oral cancer.  
Sense of coherence is broadly defined as the extent to which a person perceives life rationally 
and is able to manage stressors with available resources and considers challenges as worthwhile 
endeavors.
33, 64
  It is important for the oral health care provider to be aware that a patient must be 
personally empowered and motivated to overcome an addiction, and that sheer awareness of 
objective statistics or even personal clinical parameters may not be helpful in the cessation 
journey.  The risk factor cessation discussion should be personalized for each patient and 
discussed in such a way as to elucidate the tangible benefits of quitting. 
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In conclusion, the current study demonstrates that undergoing an oral biopsy procedure, 
as well as receiving the subsequent diagnosis, is important in the arsenal against risk factor 
addiction.  Indeed, an oral biopsy is not simply a means to determine the diagnosis of a lesion—
it is a substantial opportunity to engage patients in risk factor cessation; acquiring a diagnosis is 
more definitive in delineating risk to the patient as it provides objective, personal and tangible 
evidence of physical harm resulting from risk factor use.  The appointments proximate to oral 
biopsy are an ideal time to emphasize the implications of premalignant or malignant diagnoses.  
Moreover, and perhaps even more importantly, it follows that clinicians who are aware of this 
important relationship should be inspired to change their own behavior in a proactive way, both 
by performing more biopsies of suspicious lesions and by enhancing their patient education 
efforts to provide convincing biologic reasons why patients should quit based on the objective 
evidence of the biopsies.  In addition, differences in risk factor cessation associated with age and 
race underscore the need for clinicians to address cessation with all patients.  Armed with the 
evidence from this study, clinicians should be even more compelled not to “watch” suspicious 
lesions over time or to neglect cessation counseling for current risk factor users.  Biopsy is 
indicated for non-pathognomonic lesions that do not resolve after a reasonable period of time 
during which all sources of physical and chemical irritation are removed.  Enhanced clinical 
behavior should result in improved cessation results. 
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APPENDIX 1:  ADDITIONAL MATERIALS AND METHODS 
In the UNC oral pathology data base, all biopsy specimens are coded according to 
diagnosis and can be found by searching for the respective code(s).  As some diagnoses are more 
common than others, it was expected that the diagnosis categories would not contain equal 
numbers of potential subjects.  Once potential subjects were identified, a list was generated with 
the diagnosis, name and address of each potential subject, and each potential subject was 
assigned a study number. Gender, ethnicity and race were not part of the defining criteria for 
identifying a study population.    
The questionnaire was partially modeled off the Alaskan Native Medical Center Tobacco 
Use Questionnaire.
65
  A cover letter gave a brief description of the study and its purpose, and the 
subject was asked to complete and return the questionnaire if they consented to participate in the 
study.  A postage-paid envelope was included with the questionnaire. The questionnaire was 
created using Teleform so that returned questionnaires could be electronically scanned to record 
answers.  When a completed questionnaire was returned, it was matched with its corresponding 
study number to keep track of which potential subjects had responded. Questionnaires were 
scanned and answers electronically recorded within a secure database in the School of Dentistry.  
Data recorded included: study number, diagnosis, subject gender, subject age, subject race, 
tobacco use (type, duration, frequency), alcohol use (duration, frequency), use change since 
biopsy (quit before biopsy, no, reduced use or quit) and any knowledge of previous diagnosis of 
oral human papillomavirus.  Subject name and address were not recorded.  The original list with 
subject names and addresses was destroyed at the completion of the study. A biostatistician (Dr. 
Ceib Phillips) was consulted in study design and data analysis.  
 Some subjects had multiple diagnoses; only the most severe diagnosis was counted and 
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used to categorize the subject.  For statistical analysis, all subjects diagnosed with carcinoma 
were grouped together.  Similarly, all subjects diagnosed with dysplasia (mild, moderate or 
severe) were grouped together.   
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APPENDIX 2: QUESTIONNAIRE 
 
UNC SCHOOL OF DENTISTRY
DEPARTMENT OF DIAGNOSTIC SCIENCES AND GENERAL DENTISTRY
Latency of Oral Carcinogenesis in Tobacco Users
ID:
*This questionnaire was partially modeled off the Alaskan Native Medical Center Tobacco Use Questionnaire.
 www.anthc.org/cs/chs/tobacco/upload/FINAL-ANMC-Tobacco-use-questionnaire-May-08.PDF
Age:
Have you ever been diagnosed with human papillomavirus (HPV)? Yes No Don't know
Gender: Male Female
If you consent to participate in this study,  please use pen to complete forms.  Fill in
circles completely for the most appropriate option or fill in the blanks as needed.
Please fill in only ONE option for each question.
INSTRUCTIONS:
Please shade circles like this:
Race: African-American Asian Native American Caucasian Other
Cigarettes
Have you ever used this product? Yes No (SKIP TO NEXT SECTION - Smokeless Tobacco)
How many years have you used (did you use) it?
What is the most that you have ever used in one day?
1/2 pack or less 1 pack 1-2 packs More than 2 packs
None 1/2 pack or less 1 pack 1-2 packs More than 2 packs
How much do you currently use each day?
Have you changed your use since your biopsy?
I quit before my biopsy No Yes - I've reduced how much I use Yes - I've quit
Smokeless tobacco (chew or snuff)
Have you ever used this product? Yes No (SKIP TO NEXT SECTION - Pipes or cigars)
How many years have you used (did you use) it?
What is the most that you have ever used in one day?
less than 1 hour 1-5 hours 6-12 hours More than 12 hours
How much do you currently use each day?
Have you changed your use since your biopsy?
I quit before my biopsy No Yes - I've reduced how much I use Yes - I've quit
None less than 1 hour 1-5 hours 6-12 hours More than 12 hours
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Questionnaire - Page 2 ID:
Pipes or Cigars
Have you ever used this product? Yes No (SKIP TO NEXT SECTION - Alcoholic Drinks)
How many years have you used (did you use) it?
What is the most that you have ever used in one day?
1 cigar or pipe load 1-3 cigars or pipe loads 4 or more cigars or pipe loads
How much do you currently use each day?
Have you changed your use since your biopsy?
I quit before my biopsy No Yes - I've reduced how much I use Yes - I've quit
Alcoholic Drinks
Have you ever used this product? Yes No
How many years have you used (did you use) it?
What is the most that you have ever used in one day?
less than one drink 1-5 drinks more than 5 drinks
How much do you currently use each day?
Have you changed your use since your biopsy?
I quit before my biopsy No Yes - I've reduced how much I use Yes - I've quit
None 1 cigar or pipe load 1-3 cigars or pipe loads 4 or more cigars or pipe loads
None less than one drink 1-5 drinks more than 5 drinks
Please return this questionnaire in the provided stamped envelope.
                   Thank you for your time and consideration!
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